Akash Maniam, shared on LinekdIn:
“Brilliantly designed I-SPY2 trial – adaptive neoadjuvant treatments for early breast cancer, stratified by receptor status, DNA repair deficiency and immunogenicity and tailored according to predicted response.
The ADC/IO synergy continues to grow and this trial could really set the platform for personalised de-escalation and intensification approaches.
Great abstract at ESMO24.”
Source: Akash Maniam/LinkedIn